To include your compound in the COVID-19 Resource Center, submit it here.

Gilead: A matter of discipline

The sale of Gilead Sciences Inc.'s oncology assets to OSI Pharmaceuticals Inc. last week brings GILD full circle back to its primary focus in infectious diseases. Nevertheless, GILD got its money's worth out of the $550 million acquisition of NeXstar Pharmaceuticals Inc. in 1999, as sales of NeXstar's Ambisome liposomal amphotericin alone made up the bulk of GILD's revenues through 2000, while NeXstar's European sales force is in place to market GILD's recently approved antiviral drugs.

GILD sales for 1999,

Read the full 795 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers